CN104428417B - 利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种 - Google Patents

利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种 Download PDF

Info

Publication number
CN104428417B
CN104428417B CN201280062015.XA CN201280062015A CN104428417B CN 104428417 B CN104428417 B CN 104428417B CN 201280062015 A CN201280062015 A CN 201280062015A CN 104428417 B CN104428417 B CN 104428417B
Authority
CN
China
Prior art keywords
protein
recombinant yeast
kluyveromyces lactis
yeast
ibdv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280062015.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104428417A (zh
Inventor
K·布罗伊尼希
S-E·贝伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vero Vaccine Co Ltd
Original Assignee
Vero Vaccine Co ltd
Martin Luther Universitaet Halle Wittenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47681476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104428417(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vero Vaccine Co ltd, Martin Luther Universitaet Halle Wittenberg filed Critical Vero Vaccine Co ltd
Publication of CN104428417A publication Critical patent/CN104428417A/zh
Application granted granted Critical
Publication of CN104428417B publication Critical patent/CN104428417B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
CN201280062015.XA 2011-12-13 2012-12-12 利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种 Active CN104428417B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011121069.9 2011-12-13
DE102011121069A DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
PCT/DE2012/001205 WO2013107436A1 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Publications (2)

Publication Number Publication Date
CN104428417A CN104428417A (zh) 2015-03-18
CN104428417B true CN104428417B (zh) 2020-05-05

Family

ID=47681476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062015.XA Active CN104428417B (zh) 2011-12-13 2012-12-12 利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种

Country Status (15)

Country Link
US (1) US11065312B2 (enExample)
EP (1) EP2844759B1 (enExample)
JP (1) JP6313215B2 (enExample)
KR (1) KR102027400B1 (enExample)
CN (1) CN104428417B (enExample)
BR (1) BR112014014390B1 (enExample)
CA (1) CA2859231C (enExample)
DE (2) DE102011121069A1 (enExample)
DK (1) DK2844759T3 (enExample)
ES (1) ES2690792T3 (enExample)
MX (1) MX368484B (enExample)
PL (1) PL2844759T3 (enExample)
RU (1) RU2630620C2 (enExample)
WO (1) WO2013107436A1 (enExample)
ZA (1) ZA201405034B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP7372647B2 (ja) * 2019-06-27 2023-11-01 国立研究開発法人農業・食品産業技術総合研究機構 α‐リノレン酸産生能が向上した酵母またはその培養物
CN110646614B (zh) * 2019-07-15 2023-05-23 新乡学院 Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法
CN114870006A (zh) * 2022-04-13 2022-08-09 河北农业大学 一种etec疫苗及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110293659A1 (en) * 2008-11-14 2011-12-01 Karin Breunig Method for the oral/mucosal vaccination by means of recombinant yeasts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474676A4 (en) * 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US6234977B1 (en) 2000-01-28 2001-05-22 Michael Christy Variable-force monofilament sensory device and methods of using same
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
JP4646903B2 (ja) * 2003-03-24 2011-03-09 インターベツト・インターナシヨナル・ベー・ベー 伝染性ファブリキウス嚢病ウイルス（ｉｂｄｖ）の変異株およびワクチン
ES2242542B1 (es) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
MX2008009929A (es) 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
WO2008153339A2 (en) * 2007-06-12 2008-12-18 Univ Sungkyunkwan Found A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system
CN101638824B (zh) 2009-03-16 2012-08-08 浙江双友物流器械股份有限公司 一种耐磨织带
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110293659A1 (en) * 2008-11-14 2011-12-01 Karin Breunig Method for the oral/mucosal vaccination by means of recombinant yeasts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens;Jacob Pitcovski et al;《Vaccine》;20031231;第21卷;4736-4743 *
Infectious bursal disease virus isolate D78 segment A polyprotein gene, partial cds;Jackwood,D.J et al;《GenBank: EU162087.1》;20080709;ORIGIN *

Also Published As

Publication number Publication date
MX2014007183A (es) 2014-11-25
ZA201405034B (en) 2015-12-23
EP2844759B1 (de) 2018-07-18
JP6313215B2 (ja) 2018-04-18
CA2859231C (en) 2019-04-30
CA2859231A1 (en) 2013-07-25
MX368484B (es) 2019-10-04
BR112014014390B1 (pt) 2022-08-09
US20150190486A1 (en) 2015-07-09
KR102027400B1 (ko) 2019-10-04
WO2013107436A1 (de) 2013-07-25
US11065312B2 (en) 2021-07-20
DK2844759T3 (en) 2018-11-05
RU2014127435A (ru) 2016-02-10
WO2013107436A8 (de) 2015-01-15
EP2844759A1 (de) 2015-03-11
ES2690792T3 (es) 2018-11-22
KR20140105821A (ko) 2014-09-02
CN104428417A (zh) 2015-03-18
DE112012005213A5 (de) 2014-11-13
BR112014014390A2 (pt) 2020-12-08
PL2844759T3 (pl) 2019-01-31
RU2630620C2 (ru) 2017-09-11
JP2015507472A (ja) 2015-03-12
DE102011121069A1 (de) 2013-06-13

Similar Documents

Publication Publication Date Title
Arnold et al. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit
JP5508252B2 (ja) 鳥インフルエンザ遺伝子を含有する組み換え七面鳥ヘルペスウイルス
JP2010187679A (ja) 新規な組換えヘルペスウイルスおよび変異体ヘルペスウイルス
CN104428417B (zh) 利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
US12473562B2 (en) Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis
JP2017527306A (ja) ｒＤＮＡ ＮＴＳ基盤の遺伝子多重挿入カセットセット、及びそれを用いたＧＲＡＳ等級の組換え酵母菌株
KR101526053B1 (ko) 재조합 백신 개발을 위한 효모 야로위아 리폴리티카에서 코돈 최적화된 원형 및 n 단편-절단 형태의 노다 캡시드 단백질 생산 방법
Gebauer et al. Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme
US20220023413A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
CN102741414B (zh) 通过重组酵母口服/粘膜接种疫苗的方法
CN116492455B (zh) 非洲猪瘟病毒k421r基因及利用其制备的复制缺陷型非洲猪瘟疫苗
CN109750006A (zh) 一种犬瘟热病毒复制缺陷毒株及其构建方法
Slibinskas et al. Synthesis of mumps virus nucleocapsid protein in yeast Pichia pastoris
KR20230119635A (ko) 백신 제조를 위한 효모 플랫폼
NL2030423B1 (en) Replication-deficient strain of canine distemper virus and construction method thereof
Goudarzi et al. Expression of the VP2 gene of classical D78 infectious bursal disease virus in the methylotrophic yeast Pichia pastoris as a secretory protein
HK40037655A (en) Live-attenuated flaviruses with heterologous antigens
EA045050B1 (ru) Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis
KR20150021344A (ko) 비병원성 전염성낭병 변이 바이러스 및 이의 백신으로써의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190930

Address after: Harley

Applicant after: Vero vaccine Co., Ltd.

Address before: Harley

Applicant before: Martin-luther-universitaet Halle-wittenberg

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant